News

On 7th September, 2024 (41st) National Pharmaceutical Industry Information Conference and 2023 China Pharmaceutical Industry Top 100 List Conference was held in Chengdu. The conference was hosted by the China Pharmaceutical Industry Information Centre and undertaken by the Sichuan Provincial Department of Economy and Information Technology, with the theme of ‘Holding on to the New Future’, focusing on the cutting-edge dynamics of industrial policy, discussing the development trend of the industry, and promoting the in-depth integration of the pharmaceutical industry and the whole chain of innovation ecosystem. At the meeting, the ‘2023 List of Top 100 Enterprises in China's Pharmaceutical Industry’ was released, and Autobio, as a newcomer, was selected for the list.

In 2023, China's pharmaceutical industry is facing multiple pressures, Autobio actively responds to the changes in the market and environment, attaches great importance to innovation investment, deepens the product structure, promotes synergistic innovation, and expands the overseas market, which provides a solid guarantee for the development of the enterprise.

Attaching Great Importance to Innovation Investment

Innovation is the foundation of Autobio, for many consecutive years, the company's R&D investment accounted for more than 12% of operating income. 2023 R&D investment was 656 million, accounting for 14.77% of operating income, and in the first half of 2024, R&D investment was 333 million, accounting for 15.1% of operating income. At present, Autobio has 1,852 R&D personnel, accounting for 33.27% of the total number of employees, and has become one of the companies in the industry with more R&D personnel and active new product launches. In terms of R&D layout, Autobio has continued to improve its technology R&D system with Zhengzhou as the centre and Beijing, Shanghai, Shenzhen, Suzhou and North America R&D centres as branches, making full use of the local talent and technology advantages to enter into the development of cutting-edge technologies and products in the field of in vitro diagnostics.

Deepening Product Structure

While continuing to cultivate traditional immunology and microbiology fields, Autobio has also upgraded its products to new and leading fields: launching the fully automated biochemistry analyser AutoChem B800 series and AutoChem B2000 series to further enrich the biochemistry testing product line and meet the market demand; relying on the mature and accurate magnetic particle chemiluminescence platform, Autobio has successfully launched the Autoantibody Relying on the mature and accurate magnetic particle chemiluminescence platform, Antalis successfully launched the autoantibody detection series, which has 33 products on the market in the first phase, covering six common disease series. In addition, Antalis has accelerated the layout of the precision testing field and continued to upgrade from the traditional diagnostic field to the precision diagnostic field.

Promoting Innovation and Synergistic Development

Autobio actively promotes the construction of ‘industry-university-research-medicine’ efficient collaborative innovation ecosystem, joining hands with relevant universities, research institutes and upstream and downstream enterprises in the industry chain to lead the establishment of the National Engineering Research Centre for Detection of Emerging and Sudden Major Infectious Diseases; and leads the National Key R&D Programs of ‘R&D on Immediate Detection System for Ultra-Multiplexed Pathogens The implementation of these collaborative innovation platforms and projects has achieved rich scientific research results and laid the foundation for the sustainable development of the enterprise.

Accelerated Expansion of Overseas Markets

Autobio continues to plough into overseas markets and has obtained more than 3,000 international registration certificates, including the first EU IVDR Class C certificate for fully automated microbial mass spectrometry testing system and Class D certificate for HBsAg testing kit in China; and actively participates in international industry exhibitions to share Autobio's advanced technology and achievements in in vitro diagnostics field with international customers. At present, the company's products have entered the Middle East, Asia, Europe, the Americas, Africa and other regions. In the future, AnTuTu Bio will accelerate the global market layout and provide high-quality products and services to customers around the world.

The selection of Autobio as one of the Top 100 Enterprises in China's Pharmaceutical Industry in 2023 is a high recognition of the company's comprehensive strength and sustainable development capability. The company will continue to plough deeper into the field of in vitro diagnostics, continue to innovate, enrich the product line, promote the intelligent construction of medical laboratories, and make greater contributions to the cause of human health.